TABLE 5.
Relative risk for developing CIN2/3 or above by genotype channels of Onclarity
| HPV type | No. of CIN2/3+ cases | No. of positive cases | Relative risk to CIN2/3+ (95% CI) |
|---|---|---|---|
| 16 | 74 | 108 | 24.10 (10.84–53.57) |
| 18 | 11 | 35 | 11.05 (4.37–27.96) |
| 45 | 3 | 9 | 11.72 (3.48–39.50) |
| 33/58 | 47 | 102 | 16.20 (7.16–36.65) |
| 31 | 9 | 16 | 19.78 (8.05–48.62) |
| 56/59/66 | 12 | 71 | 5.94 (2.32–15.25) |
| 51 | 7 | 32 | 7.69 (2.76–21.44) |
| 52 | 30 | 103 | 10.24 (4.40–23.83) |
| 35/39/68 | 22 | 64 | 12.09 (5.12–28.52) |
| 16 and 33/58 | 10 | 11 | 31.97 (14.21–71.90) |
| 33/58 and 35/39/68 | 6 | 9 | 8.79 (2.50–30.93) |
| 33/58 and 52 | 11 | 18 | 21.49 (9.00–51.33) |
| 35/39/68 and 52 | 6 | 10 | 21.10 (8.27–83.86) |
| 16 and 52 | 7 | 13 | 18.94 (7.43–48.26) |
| hrHPV | 157 | 394 | 14.01 (6.31–31.12) |
| Negative | 6 | 211 | Reference group |